GENEVA – The Global Fund to Fight AIDS, Tuberculosis and Malaria has named Rahul Singhal, a senior global risk management and treasury executive, as its new Chief Risk Officer.
Mr. Singhal has 28 years of experience in risk management in the financial services industry, building and leading risk management teams, and executing complex global initiatives including acquisitions and strategic investments. Mr. Singhal joined the Global Fund in October 2015 as Deputy Chief Risk Officer, and has been Acting Chief Risk Officer since January 2016.
“Rahul brings unparalleled experience and perspective on risk,” said Mark Dybul, Executive Director of the Global Fund. “His tremendous expertise and knowledge will guide us through the increasingly complex challenges we face, and it’s great that he can serve in this role.”
The Chief Risk Officer position was created in 2012 to strengthen risk management at the Global Fund. The Chief Risk Officer is responsible for supervising overall risk management, and serves on the Management Executive Committee.
At Bank of America, Mr. Singhal served in numerous positions overseeing credit and market risk, counterparty risk and operational risk over a period that included two severe financial crises – in 1997 in Asia and in 2008 globally. Originally from India, he holds an MBA from the Indian Institute of Management in Calcutta and a Bachelor of Technology from the Indian Institute of Technology in New Delhi.
The Roll Back Malaria (RBM) Partnership has named a new board to lead the global organization into a new era and drive momentum to end malaria for good.
The intensified, collaborative effort by RBM partners to support affected countries to end malaria is saving millions of lives, increasing attendance at school, improving worker productivity and boosting local economies. But malaria remains a serious public health threat. Eliminating malaria is critical to achieving the Sustainable Development Goals, and must remain a key priority for the global development community.
In the middle of December 2013, the RBM Board commissioned an external evaluation to ensure the Partnership was well positioned to drive continued momentum towards a malaria-free world This evaluation concluded that significant adjustments to RBM’s structure would be necessary to sustain its successes and build on them to deliver on the ambitious goals and objectives of the 2030 WHO Global Technical Strategy (GTS) and accompanying RBM Action and Investment to defeat Malaria (AIM).
After a period of extensive consultation, the RBM Board agreed at its 29th Meeting in December 2015 on a new governance architecture. This included the establishment of a reconstituted Partnership Board, which could take advantage of the tremendous skill, energy and effectiveness of its partners and lead the organization into a new era with a focus on ending malaria. As a result, a transparent public nomination process was announced in January 2016 to identify outstanding new Board members.
The response to the call for nominations was overwhelming: more than 100 nominations were received from the wide malaria and related multi-sectoral community, including government, civil society, non-government organisations, the private sector, donor funding organisations (governmental, multilateral or private philanthropic), and research and academia.
After a robust assessment and selection process 13 individuals have been chosen to take the revitalised Partnership forward, along with an additional Board member to be named by the WHO:
- Mr Elhadj As Sy, Secretary General, International Federation of Red Cross and Red Crescent Societies
- Mr Simon Bland, Director – New York Office, UNAIDS
- Prof Awa Coll-Seck, Minister of Health & Social Welfare, Senegal
- Mr Kieran Daly, Deputy Director: Global Policy & Advocacy – Malaria, HIV, TB and the Global Fund, Bill & Melinda Gates Foundation
- Mr Paolo Gomes, Chairman, Paulo Gomes and Partners, former Executive Director, World Bank
- Dr Richard Nchabi Kamwi, Elimination 8 Ambassador, former Minister of Health, Namibia
- Dr Altaf Lal, Senior Advisor on Global Health and Innovation, Sun Pharmaceuticals Industries
- Dr Winnie Mpanju-Shumbusho, former Assistant Director General – Malaria, HIV, TB, NTDs, WHO
- Mr Ray Nishimoto, President of Health & Crop Sciences Sector, Sumitomo Chemical
- Dr David Reddy, Chief Executive, Medicines for Malaria Venture
- Mr Gu Xueming, President of the Chinese Academy of International Trade and Economic Cooperation
- HE Yongyuth Yuthavong, Deputy Prime Minister, Thailand
- Rear Admiral Tim Ziemer USN (ret), Global Co-ordinator, US President’s Malaria Initiative
This new Partnership Board includes individuals with deep expertise and experience at a senior decision-making level as well as representation from across the Partnership, including malaria-affected countries, private sector, civil society, donor funding organisations, and entities outside the malaria and health sectors, civil society and donors.
In confirming the result of the vote the current Board Chair the Honorable Victor Makwenge Kaput stated that he believed that the individuals selected:
“Represented an impressive group of distinctly qualified individuals who will be well-positioned to take the RBM Partnership to a new level in its evolution.”
The new Board are expected to assume responsibility for leading the Partnership from April 2016 and RBM are confident that the changes to the architecture of the Partnership will result in a strengthened malaria partnership well-positioned to support the delivery of the ambitious goal of Ending Malaria for Good.
By Scott Barnhart
The world is too complicated for disease-specific approaches to health, as the ravages of Ebola in weak health systems have shown. A health-system strengthening approach will ensure that, especially in times of austerity, there are local institutions and infrastructure in place to provide care for all.
|The President’s Emergency Plan for AIDS Relief (PEPFAR) 3.0 has embarked on an important refocusing to achieve epidemic control through 90-90-90 (90% of HIV-positive individuals knowing their status, 90% of those receiving antiretroviral therapy, and 90% of those achieving viral suppression).1 and 2 Despite good intentions, the implementation is creating health-system disruption. For example, in Zimbabwe, a voluntary medical male circumcision programme will now serve ten instead of 21 districts. Ambassador Birx, referring to these programme cuts as “efficiencies”, touted that funds will be freed up “for the greatest impact.3” Although this might optimise impact in areas of the highest HIV/AIDS burden, medical sites are being triaged, with patients losing services and investments being wasted. Concentration on fewer districts also leads to poaching of health workers from already understaffed sites elsewhere.|
On International Women’s Day, 8 March, we mark progress in the fight for gender equality, and we face a reality that is still starkly unjust. Today, 62 million girls are still denied the right to education, half a billion women cannot read and 155 countries still have laws that discriminate against women.
That is unacceptable, and we must work together to change it. In a report entitled “Poverty is Sexist,” published by ONE, leaders in global development call on the world to act on gender inequality and create more opportunity for women.
Gender inequality often leaves women and girls prone to diseases and other life-threatening conditions. Adolescent girls and young women are disproportionately affected by HIV. Currently, more than 7,000 young women and girls are getting infected with HIV every week.
We must address social factors that put adolescent girls and young women at increased risk for infectious diseases, and provide them with more opportunities in life. Education can make a transformative difference, and keeping girls in school can create a solid foundation for better choices on building a career, owning property, and deciding whether and when to marry and have children. We must strive for a world where human beings, no matter their gender, can live a successful and healthy life.
By Carole Leach-Lemens
Engaging lay counsellors to provide a combination package of evidence-based interventions in Nyanza, Kenya and addressing partner disclosure, as well as pre-treatment education about the benefits of antiretroviral therapy (ART) for maternal and child health in Malawi’s Option B+ programme, improved retention in care and reduced loss to follow-up of mothers with HIV and their infants, studies presented last week at the Conference on Retroviruses and Opportunistic Infections (CROI 2016) in Boston show.
Poor retention in care of mothers with HIV and their infants across the prevention of mother-to-child transmission (PMTCT)/paediatric care continuum continues to undermine what is otherwise a remarkable success. If retention is not adequately addressed, programme success and maternal and infant health are threatened. In resource-poor settings, studies have shown 17% of pregnant women with HIV initiated on ART do not return after their first antenatal care visit; one third of women with HIV who give birth in a clinic are lost to follow-up three months after delivery.